Binimetinib

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Binimetinib, sold under the brand name Mektovi, is an anti-cancer medication used to treat various cancers. Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. Inappropriate activation of the pathway has been shown to occur in many cancers.

In June 2018 it was approved by the FDA in combination with encorafenib for the treatment of patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma. In October 2023, it was approved by the FDA for treatment of NSCLC with a BRAF V600E mutation in combination with encorafenib. It was developed by Array Biopharma and Pfizer.

Binimetinib, sold under the brand name Mektovi, is an anti-cancer medication used to treat various cancers. Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. Inappropriate activation of the pathway has been shown to occur in many cancers.

In June 2018 it was approved by the FDA in combination with encorafenib for the treatment of patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma. In October 2023, it was approved by the FDA for treatment of NSCLC with a BRAF V600E mutation in combination with encorafenib. It was developed by Array Biopharma and Pfizer.

Synthesis

The synthesis of Binimetinib was recently reported: The reaction of 2,3,4-trifluoro-5-nitrobenzoic acid [197520-71-1] (1) with O-(2-tert-butoxyethyl)hydroxylamine [1023742-13-3] (2) was achieved using CDI coupling agent and diisopropylethylamine to give 2,3,4-trifluoro-N-[2-[(2-methylpropan-2-yl)oxy]ethoxy]-5-nitrobenzamide, PC141452301 (3). Both of the activated fluorine atoms were displaced using ammonium hydroxide requiring the pressurized conditions of a steel bomb to furnish 2,4-diamino-3-fluoro-N-[2-[(2-methylpropan-2-yl)oxy]ethoxy]-5-nitrobenzamide, PC141452304 (4).

Formation of the benzimidazole with formic acid with a catalytic amount of palladium hydroxide on carbon gave PC141452305 (5). The selective arylation with 4-bromo-2-fluoro-1-iodobenzene [105931-73-5] (6) in the presence of a highly specialized Pd2(dba)3 Xantphos catalyst exclusively yielded the hindered primary aniline, PC141452303 (7).

The methylation of the benzimidazole secondary nitrogen with methyl iodide in the presence of potassium carbonate occurred chemoselectively. Treatment with an excess of aqueous phosphoric acid cleaved the terminal t-butyl ether completing the synthesis of binimetinib (8).

Text derived from https://en.wikipedia.org/w/index.php?oldid=1348402621 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

14 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.